Headlines about Corvus Pharmaceuticals (NASDAQ:CRVS) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Corvus Pharmaceuticals earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.1366138008552 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

NASDAQ:CRVS traded up $0.01 on Wednesday, hitting $11.04. The company’s stock had a trading volume of 29,622 shares, compared to its average volume of 108,995. The firm has a market capitalization of $326.96 million, a price-to-earnings ratio of -4.06 and a beta of -2.00. Corvus Pharmaceuticals has a one year low of $7.42 and a one year high of $17.64.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings data on Thursday, May 3rd. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.11. equities research analysts forecast that Corvus Pharmaceuticals will post -2.64 earnings per share for the current fiscal year.

CRVS has been the topic of several analyst reports. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Friday, May 4th. ValuEngine upgraded Corvus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, June 7th. Jefferies Financial Group initiated coverage on Corvus Pharmaceuticals in a report on Tuesday, June 5th. They set a “buy” rating and a $17.00 target price on the stock. Finally, BidaskClub upgraded Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Corvus Pharmaceuticals presently has an average rating of “Hold” and an average price target of $17.75.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Insider Buying and Selling by Quarter for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.